New Immune Approach for Treatment of Alzheimer's Disease

New hope for a much needed new approach for tackling Alzheimer's disease will be discussed in detail this week at a new medical conference in Philadelphia. At the inaugural Targeting Alzheimer's with Novel Therapeutics conference, to be held as part of the 8th annual World Pharmaceutical Congress, Edward Tobinick MD, Director of the Institute for Neurological Research, a private medical group, inc. in Los Angeles, will present the latest data on a revolutionary new immune approach for treatment of Alzheimer's disease.

Los Angeles, CA (PRWEB) June 8, 2009 -- New hope for a much needed new approach for tackling Alzheimer's disease will be discussed in detail this week at the inaugural Targeting Alzheimer's with Novel Therapeutics conference, to be held as part of the 8th annual World Pharmaceutical Congress in Philadelphia on June 10 and 11. On the second day of this conference, after presentations by researchers from Abbott Laboratories, Medivation, Epix Pharmaceuticals, the Buck Institute, Cleveland Clinic, and others, Edward Tobinick MD, Director of the Institute for Neurological Research®, (INR®), a private medical group, inc. in Los Angeles, will present the latest data on a revolutionary new immune approach for treatment of Alzheimer's disease.

Dr. Tobinick's presentation, entitled TNF modulation for treatment of Alzheimer's Disease, will review the remarkable results which have been documented using perispinal administration of etanercept, a therapeutic developed through recombinant DNA biotechnology, for treatment of Alzheimer's disease (1-7). This patented (8) off-label treatment method, invented and developed at the INR, may produce clinical improvement within minutes (1-6).

Localized administration of etanercept for treatment of neurological disorders is a novel concept which was invented by Dr. Tobinick a decade ago (8). The proof-of-concept of these novel methods which Dr. Tobinick invented (8, 9), which include both perispinal and epidural etanercept for treatment of sciatica (see INR sciatica website) (8), are now supported by additional, independent studies from academic centers, including a new randomized, double-blind, placebo-controlled clinical trial from Johns Hopkins and Walter Reed Army Medical Center (10, 11).

The prospect of a new, immune-based approach for treatment of Alzheimer's is exciting. Recent reports of the ability of etanercept to penetrate rapidly into the cerebrospinal fluid within the brain in animal studies now provide new insight into the potential mechanisms underlying the rapid clinical effects of etanercept in patients with Alzheimer's disease (12). Patient treatment is currently available at the Institute in Los Angeles, and at the Institute's new office in Newport Beach, California. Further information is available on the website of the INR, at Institute for Neurological Research in Los Angeles website.

References

8. U.S. patents 6,015,557; 6,177,077; 6,419,944; 6,537,549; 6,982,089; 7,214,658, and Australian patent 758,523 issued to Edward Tobinick MD and assigned to TACT IP, LLC, and additional patents and related applications, assigned to TACT IP, LLC.

# # #
Contact Information
David Rosshirt
Institute for Neurological Research private medical grp. inc
http://www.nrimed.com
310.824.6199

Online Web 2.0 Version
You can read the online version of this press release here.